VRTX$438.6
Chart
Performance
Key Stats
AI VRTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyVertex Pharmaceuticals demonstrates strong fundamental performance and a promising thematic outlook in biotechnology, particularly in genetic therapies. While current technical indicators suggest some short-term headwinds or consolidation, the long-term prospects remain robust. Suitable for investors seeking growth in the healthcare sector.
Thematic
Vertex Pharmaceuticals is well-positioned within several high-growth thematic areas, including precision medicine, rare disease treatments, and innovative drug development. Its focus on genetically defined diseases like cystic fibrosis and its expansion into areas like sickle cell disease and type 1 diabetes highlight strong thematic alignment.
Fundamental
Vertex Pharmaceuticals demonstrates strong financial health with substantial cash reserves, consistent revenue growth, and a solid balance sheet. The company has a history of profitable operations, though recent quarters have shown some variability in net income, potentially due to R&D investments or specific product launch costs.
Technical
Vertex Pharmaceuticals exhibits mixed technical signals. While it has shown strong performance over the past 6 months and year-to-date, recent price action indicates a potential short-term downtrend or consolidation. Key moving averages are generally indicating a bearish to neutral sentiment on shorter timeframes.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 90 |
| Rare Disease Focus | 95 |
| Genetic Therapies | 88 |
| Disease Modification | 85 |
| Competitive Landscape | 75 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 80 |
| Growth | 85 |
| Balance Sheet Health | 95 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 45 |
| Support & Resistance | 65 |
| Volume | 70 |
| Analyst Sentiment | 80 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
Vertex Pharmaceuticals (VRTX) has a history of exceeding earnings per share (EPS) estimates, with 9 out of the last 10 quarters reporting positive surprises. The most recent quarter showed an EPS surprise of 17.15% in Q2 2024.
Strong Year-to-Date Performance
VRTX has demonstrated robust growth with a Year-to-Date (YTD) performance of 16.39%, significantly outperforming broader market indices over the same period.
Bearish Points (7)
Significant EPS Miss in Q3 2024
Vertex Pharmaceuticals reported a substantial earnings miss in Q3 2024, with reported EPS of -12.83 against an estimate of 2.94, representing a -536.12% surprise. This indicates potential headwinds or execution challenges.
Elevated Price-to-Sales Ratio
The Price-to-Sales (PS) ratio for 2024 is 9.4, which is relatively high and suggests that investors are paying a premium for the company's revenue, potentially indicating overvaluation if growth falters.
Calendar
August 2025
5
Next Earnings Date
H: $4.63
A: $4.25
L: $3.92
H: 2.98B
A: 2.91B
L: 2.80B
Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Seasonals
Price Target
500.23 USD
The 39 analysts offering 1 year price forecasts for VRTX have a max estimate of 621.00 and a min estimate of 330.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct co-developer of Casgevy (exa-cel) with Vertex for sickle cell disease and beta-thalassemia, representing a major pipeline asset.
Weight: 95
Gene therapy company focused on severe genetic diseases, including sickle cell disease and beta-thalassemia, making it a direct competitor/peer in the exa-cel therapeutic space.
Weight: 93
Dedicated to developing and commercializing innovative therapies for rare genetic diseases, a core therapeutic area for Vertex.
Weight: 92
A leader in RNA interference (RNAi) therapeutics for rare genetic diseases, sharing a similar advanced modality and therapeutic focus to Vertex.